5Hsu CY,Chertow GM,Curhan GC. Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency[J].Kidney International,2002,(05):1567-1576.
6Sarnak MJ,Katz R,Stehman-Breen CO. Cystatin C concentrati on as arisk factor for heart failure in older adults[J].Annals of Internal Medicine,2005,(02):497-505.
5Jovanovic D,Krstivojevic P,Obradovic I, et al. Serum eystatin C and beta2-microglobulin as markers of glomerular filtration rate. Ren Fail, 2003,25( 1 ):123-133.
6Smilde TD, Hillege HL,Navis G, et al. Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonat activation and survival.Am Heart J, 2004,148( 1 ):165-172.
7Bskenkamp A,van Wijk JA, Lentze MJ, et al.Effect of corticosteroid therapy on serum Cystatin C and β 2-microglobulin concentrations.Clin Chem, 2002,48 (7): 1123-1126.
8Neumann J, Ligtenberg G, Klein Ⅱ,et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int, 2004,65 (5):1568-1576.
9Bargnoux AS,Klouche K,Fareh J ,et al. Prohormone brain natri uretic peptide (proBNP), BNP and N-terminal prolBNP circular ing levels in chronic hemodialysis patients. Correlation with yen triculat function, fluid removal and effect of hemodiafiltration. Clin Chem Lab Med,2008,46(2):1 019-1 024.
10Paniagua R,Amato D, Mujais S, et al. Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clin J Am Soc Nephrol, 2008,3 (2) : 407-415.
